EquityIndex FundsVery High Risk
Regular
NAV (21-Jan-25)
Returns (Since Inception)
Fund Size
₹132 Cr
Expense Ratio
1.11%
ISIN
INF277KA1BD0
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+21.08%
— (Cat Avg.)
Equity | ₹132.47 Cr | 100.38% |
Others | ₹-0.5 Cr | -0.38% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹19.14 Cr | 14.50% |
Lupin Ltd | Equity | ₹12.97 Cr | 9.83% |
Fortis Healthcare Ltd | Equity | ₹8.56 Cr | 6.49% |
Aurobindo Pharma Ltd | Equity | ₹8.52 Cr | 6.46% |
Alkem Laboratories Ltd | Equity | ₹6.73 Cr | 5.10% |
Mankind Pharma Ltd | Equity | ₹6.21 Cr | 4.70% |
Glenmark Pharmaceuticals Ltd | Equity | ₹5.54 Cr | 4.19% |
Laurus Labs Ltd | Equity | ₹5.42 Cr | 4.10% |
Ipca Laboratories Ltd | Equity | ₹5.26 Cr | 3.98% |
Biocon Ltd | Equity | ₹3.75 Cr | 2.84% |
Piramal Pharma Ltd | Equity | ₹3.74 Cr | 2.84% |
Abbott India Ltd | Equity | ₹3.55 Cr | 2.69% |
Syngene International Ltd | Equity | ₹3.54 Cr | 2.68% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹3.35 Cr | 2.54% |
Suven Pharmaceuticals Ltd | Equity | ₹3.3 Cr | 2.50% |
Gland Pharma Ltd | Equity | ₹3.23 Cr | 2.45% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.01 Cr | 2.28% |
Natco Pharma Ltd | Equity | ₹2.87 Cr | 2.17% |
Ajanta Pharma Ltd | Equity | ₹2.82 Cr | 2.14% |
Dr. Lal PathLabs Ltd | Equity | ₹2.52 Cr | 1.91% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.51 Cr | 1.90% |
Poly Medicure Ltd | Equity | ₹2.27 Cr | 1.72% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹2.13 Cr | 1.62% |
Global Health Ltd | Equity | ₹2.05 Cr | 1.55% |
Narayana Hrudayalaya Ltd | Equity | ₹1.97 Cr | 1.50% |
Granules India Ltd | Equity | ₹1.96 Cr | 1.48% |
Rainbow Childrens Medicare Ltd | Equity | ₹1.71 Cr | 1.29% |
Alembic Pharmaceuticals Ltd | Equity | ₹1.36 Cr | 1.03% |
Sanofi India Ltd | Equity | ₹1.27 Cr | 0.96% |
Metropolis Healthcare Ltd | Equity | ₹1.23 Cr | 0.93% |
Net Current Liabilities | Cash - Collateral | ₹-0.98 Cr | 0.74% |
A) Repo | Cash - Repurchase Agreement | ₹0.48 Cr | 0.36% |
Large Cap Stocks
4.71%
Mid Cap Stocks
66.51%
Small Cap Stocks
29.16%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹132.47 Cr | 100.38% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since April 2024
Since December 2024
ISIN INF277KA1BD0 | Expense Ratio 1.11% | Exit Load No Charges | Fund Size ₹132 Cr | Age 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹620.49 Cr | 12.9% |
ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹620.49 Cr | 12.2% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹502.65 Cr | 4.7% |
SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹740.33 Cr | 12.3% |
DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1896.35 Cr | 7.5% |
SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1301.32 Cr | 13.2% |
SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹740.33 Cr | 13.0% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹502.65 Cr | 5.3% |
DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1896.35 Cr | 8.1% |
SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1301.32 Cr | 12.5% |
Your principal amount will be at Very High Risk
EquityIndex FundsVery High Risk
Regular
NAV (21-Jan-25)
Returns (Since Inception)
Fund Size
₹132 Cr
Expense Ratio
1.11%
ISIN
INF277KA1BD0
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+21.08%
— (Cat Avg.)
Equity | ₹132.47 Cr | 100.38% |
Others | ₹-0.5 Cr | -0.38% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹19.14 Cr | 14.50% |
Lupin Ltd | Equity | ₹12.97 Cr | 9.83% |
Fortis Healthcare Ltd | Equity | ₹8.56 Cr | 6.49% |
Aurobindo Pharma Ltd | Equity | ₹8.52 Cr | 6.46% |
Alkem Laboratories Ltd | Equity | ₹6.73 Cr | 5.10% |
Mankind Pharma Ltd | Equity | ₹6.21 Cr | 4.70% |
Glenmark Pharmaceuticals Ltd | Equity | ₹5.54 Cr | 4.19% |
Laurus Labs Ltd | Equity | ₹5.42 Cr | 4.10% |
Ipca Laboratories Ltd | Equity | ₹5.26 Cr | 3.98% |
Biocon Ltd | Equity | ₹3.75 Cr | 2.84% |
Piramal Pharma Ltd | Equity | ₹3.74 Cr | 2.84% |
Abbott India Ltd | Equity | ₹3.55 Cr | 2.69% |
Syngene International Ltd | Equity | ₹3.54 Cr | 2.68% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹3.35 Cr | 2.54% |
Suven Pharmaceuticals Ltd | Equity | ₹3.3 Cr | 2.50% |
Gland Pharma Ltd | Equity | ₹3.23 Cr | 2.45% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.01 Cr | 2.28% |
Natco Pharma Ltd | Equity | ₹2.87 Cr | 2.17% |
Ajanta Pharma Ltd | Equity | ₹2.82 Cr | 2.14% |
Dr. Lal PathLabs Ltd | Equity | ₹2.52 Cr | 1.91% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.51 Cr | 1.90% |
Poly Medicure Ltd | Equity | ₹2.27 Cr | 1.72% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹2.13 Cr | 1.62% |
Global Health Ltd | Equity | ₹2.05 Cr | 1.55% |
Narayana Hrudayalaya Ltd | Equity | ₹1.97 Cr | 1.50% |
Granules India Ltd | Equity | ₹1.96 Cr | 1.48% |
Rainbow Childrens Medicare Ltd | Equity | ₹1.71 Cr | 1.29% |
Alembic Pharmaceuticals Ltd | Equity | ₹1.36 Cr | 1.03% |
Sanofi India Ltd | Equity | ₹1.27 Cr | 0.96% |
Metropolis Healthcare Ltd | Equity | ₹1.23 Cr | 0.93% |
Net Current Liabilities | Cash - Collateral | ₹-0.98 Cr | 0.74% |
A) Repo | Cash - Repurchase Agreement | ₹0.48 Cr | 0.36% |
Large Cap Stocks
4.71%
Mid Cap Stocks
66.51%
Small Cap Stocks
29.16%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹132.47 Cr | 100.38% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since April 2024
Since December 2024
ISIN INF277KA1BD0 | Expense Ratio 1.11% | Exit Load No Charges | Fund Size ₹132 Cr | Age 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹620.49 Cr | 12.9% |
ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹620.49 Cr | 12.2% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹502.65 Cr | 4.7% |
SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹740.33 Cr | 12.3% |
DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1896.35 Cr | 7.5% |
SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1301.32 Cr | 13.2% |
SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹740.33 Cr | 13.0% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹502.65 Cr | 5.3% |
DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1896.35 Cr | 8.1% |
SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1301.32 Cr | 12.5% |
Get your portfolio reviewed by experts